Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share

Reuters

Nov 13

Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share

Overview

Celcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectations
Company's operating expenses increased to $42.8 mln in Q3 2025
Celcuity on track to submit NDA for gedatolisib in Q4 2025

Outlook

Celcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or Q2 2026
Celcuity plans to submit NDA for gedatolisib in Q4 2025

Result Drivers

FINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structure

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Adjusted EPS	Beat	-$0.78	-$1.02 (7 Analysts)
Q3 EPS		-$0.92
Q3 Adjusted Net Income	Beat	-$37.20 mln	-$43 mln (7 Analysts)
Q3 Net Income		-$43.80 mln
Q3 Operating Expenses		$42.80 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Celcuity Inc is $78.00, about 1.5% below its November 11 closing price of $79.17

Press Release: ID:nGNX9HLwC2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583588271"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583588271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583588271?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583588271","market":"us","top_or_hot":-1,"title":"Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share </title></head><body><p><span>Overview</span></p><ul><li><p>Celcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectations</p></li><li><p>Company's operating expenses increased to $42.8 mln in Q3 2025</p></li><li><p>Celcuity on track to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Celcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Celcuity plans to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structure</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$0.78</p></td><td><p>-$1.02 (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.92</p></td><td></td></tr><tr><td><p>Q3 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$37.20 mln</p></td><td><p>-$43 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$43.80 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$42.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a> is $78.00, about 1.5% below its November 11 closing price of $79.17</p></li></ul><p>Press Release: <span>ID:nGNX9HLwC2</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share </title></head><body><p><span>Overview</span></p><ul><li><p>Celcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectations</p></li><li><p>Company's operating expenses increased to $42.8 mln in Q3 2025</p></li><li><p>Celcuity on track to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Celcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Celcuity plans to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structure</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$0.78</p></td><td><p>-$1.02 (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.92</p></td><td></td></tr><tr><td><p>Q3 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$37.20 mln</p></td><td><p>-$43 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$43.80 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$42.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a> is $78.00, about 1.5% below its November 11 closing price of $79.17</p></li></ul><p>Press Release: <span>ID:nGNX9HLwC2</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CELC","symbol_name":"Celcuity Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO12O:1","article_id":"2583588271","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583588271","pubTimestamp":1762981905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per shareOverviewCelcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectationsCompany's operating ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CELC":"Celcuity Inc","BK4139":"生物科技"},"translate_title":"癌症诊断公司Celcuity公布第三季度调整后每股亏损低于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":0.9},"content_text":"Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share OverviewCelcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectationsCompany's operating expenses increased to $42.8 mln in Q3 2025Celcuity on track to submit NDA for gedatolisib in Q4 2025OutlookCelcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or Q2 2026Celcuity plans to submit NDA for gedatolisib in Q4 2025Result DriversFINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structureKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Adjusted EPSBeat-$0.78-$1.02 (7 Analysts)Q3 EPS-$0.92Q3 Adjusted Net IncomeBeat-$37.20 mln-$43 mln (7 Analysts)Q3 Net Income-$43.80 mlnQ3 Operating Expenses$42.80 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Celcuity Inc is $78.00, about 1.5% below its November 11 closing price of $79.17Press Release: ID:nGNX9HLwC2For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}